Insulin-Like Growth Factor Binding Protein 2 Predicts Right Ventricular Reverse Remodeling and Improvement of Concomitant Tricuspid Regurgitation After Transcatheter Edge-to-Edge Mitral Valve Repair

Overview

Journal Clin Cardiol

Specialty Cardiology & Vascular Diseases

Date 2024 Nov 27

PMID 39600082

Authors

Matthias Groger

Dominik Felbel

Michael Paukovitsch

Leonhard Moritz Schneider

Sinisa Markovic

Wolfgang Rottbauer

Mirjam Kessler

Affiliations

Soon will be listed here.

Abstract

Background: Concomitant right ventricular (RV) failure and tricuspid regurgitation (TR) are common comorbidities in patients undergoing mitral valve transcatheter edge-to-edge repair (M-TEER) and are associated with worse prognosis. Improvement of TR after M-TEER occurs frequently, however determinants of this course are poorly understood. This study aimed to analyze serum biomarkers that are differentially regulated in patients with TR and to identify biomarkers predictive of the course of TR after M-TEER.

Methods And Results: Biomarker expression was analyzed in 242 prospectively included patients undergoing M-TEER. Patients with moderate-to-severe TR had significant comorbidities (median EuroSCORE II 5.2 in patients with severe TR, 4.9 in moderate TR, 3.2 in no/mild TR; p = 0.002) and a large number of biomarkers was upregulated including IGFBP-2 (1.4-fold in severe TR compared to no/mild TR, p = 0.005). Echocardiographic follow-up 3 months after M-TEER was carried out in 99 patients. RV reverse remodeling (RVRR) as defined by improvement of concomitant TR by at least one grade and/or RV diameter downsizing of at least 10% compared to baseline was seen in 50 patients (50.5%). IGFBP-2 (Odds Ratio 2.078) and presence of chronic pulmonary disease (Odds Ratio 15.341) proved independent predictors of non-development of RVRR within 3 months after M-TEER.

Conclusions: In patients undergoing M-TEER with concomitant moderate or severe TR, numerous cardiometabolic biomarkers including IGFBP-2 are upregulated. Higher levels of IGFBP-2 at baseline are independently associated with persistent TR and/or RV dilation after M-TEER.

References

Llucia-Valldeperas A, van Wezenbeek J, Goumans M, de Man F . The battle of new biomarkers for right heart failure in pulmonary hypertension: is the queen of hearts NT-proBNP defeated at last?. Eur Respir J. 2021; 57(4). DOI: 10.1183/13993003.04277-2020. View

Ohno Y, Attizzani G, Capodanno D, Cannata S, Dipasqua F, Imme S . Association of tricuspid regurgitation with clinical and echocardiographic outcomes after percutaneous mitral valve repair with the MitraClip System: 30-day and 12-month follow-up from the GRASP Registry. Eur Heart J Cardiovasc Imaging. 2014; 15(11):1246-55. DOI: 10.1093/ehjci/jeu114. View

Groger M, Zeiml K, Schneider L, Rottbauer W, Markovic S, Kessler M . Impact of concomitant tricuspid regurgitation on outcome after edge-to-edge mitral valve repair. Catheter Cardiovasc Interv. 2023; 102(3):528-537. DOI: 10.1002/ccd.30787. View

Besler C, Blazek S, Rommel K, Noack T, von Roeder M, Luecke C . Combined Mitral and Tricuspid Versus Isolated Mitral Valve Transcatheter Edge-to-Edge Repair in Patients With Symptomatic Valve Regurgitation at High Surgical Risk. JACC Cardiovasc Interv. 2018; 11(12):1142-1151. DOI: 10.1016/j.jcin.2018.04.010. View

Barutaut M, Fournier P, Peacock W, Evaristi M, Caubere C, Turkieh A . Insulin-like Growth Factor Binding Protein 2 predicts mortality risk in heart failure. Int J Cardiol. 2019; 300:245-251. DOI: 10.1016/j.ijcard.2019.09.032. View

Adamson C, Welsh P, Docherty K, de Boer R, Diez M, Drozdz J . IGFBP-7 and Outcomes in Heart Failure With Reduced Ejection Fraction: Findings From DAPA-HF. JACC Heart Fail. 2023; 11(3):291-304. DOI: 10.1016/j.jchf.2022.09.004. View

Geyer M, Keller K, Bachmann K, Born S, Tamm A, Ruf T . Concomitant tricuspid regurgitation severity and its secondary reduction determine long-term prognosis after transcatheter mitral valve edge-to-edge repair. Clin Res Cardiol. 2021; 110(5):676-688. PMC: 8099767. DOI: 10.1007/s00392-020-01798-4. View

von Bardeleben R, Lurz P, Sorajja P, Ruf T, Hausleiter J, Sitges M . Two-Year Outcomes for Tricuspid Repair With a Transcatheter Edge-to-Edge Valve Repair From the Transatlantic TRILUMINATE Trial. Circ Cardiovasc Interv. 2023; 16(8):e012888. DOI: 10.1161/CIRCINTERVENTIONS.122.012888. View

Groger M, Hirsch K, Felbel D, Paukovitsch M, Schneider L, Markovic S . Predictors of Improvement in Concomitant Tricuspid Regurgitation Following Transcatheter Edge-to-Edge Mitral Valve Repair. J Clin Med. 2023; 12(19). PMC: 10573471. DOI: 10.3390/jcm12196191. View

10.

Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J . 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2021; 43(7):561-632. DOI: 10.1093/eurheartj/ehab395. View

11.

Stone G, Adams D, Abraham W, Kappetein A, Genereux P, Vranckx P . Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 2: endpoint definitions: A consensus document from the Mitral Valve Academic Research Consortium. Eur Heart J. 2015; 36(29):1878-91. DOI: 10.1093/eurheartj/ehv333. View

12.

Schneider L, Nicoleta N, Schepperle N, Paukovitsch M, Haide U, Feuerabendt S . Implications of concomitant obstructive or restrictive pulmonary diseases on functional and clinical results after MitraClip. Catheter Cardiovasc Interv. 2021; 98(7):E1000-E1006. DOI: 10.1002/ccd.29893. View

13.

Zhang L, Smyth D, Al-Khalaf M, Blet A, Du Q, Bernick J . Insulin-like growth factor-binding protein-7 (IGFBP7) links senescence to heart failure. Nat Cardiovasc Res. 2024; 1(12):1195-1214. PMC: 11358005. DOI: 10.1038/s44161-022-00181-y. View

14.

Frangieh A, Gruner C, Mikulicic F, Attinger-Toller A, Tanner F, Taramasso M . Impact of percutaneous mitral valve repair using the MitraClip system on tricuspid regurgitation. EuroIntervention. 2016; 11(14):e1680-6. DOI: 10.4244/EIJV11I14A320. View

15.

Kavsur R, Iliadis C, Spieker M, Brachtendorf B, Tiyerili V, Metze C . Predictors and prognostic relevance of tricuspid alterations in patients undergoing transcatheter edge-to-edge mitral valve repair. EuroIntervention. 2021; 17(10):827-834. PMC: 9724950. DOI: 10.4244/EIJ-D-20-01094. View

16.

Soler M, Minana G, Santas E, Nunez E, de la Espriella R, Valero E . CA125 outperforms NT-proBNP in acute heart failure with severe tricuspid regurgitation. Int J Cardiol. 2020; 308:54-59. DOI: 10.1016/j.ijcard.2020.03.027. View

17.

Sanders-van Wijk S, Tromp J, Beussink-Nelson L, Hage C, Svedlund S, Saraste A . Proteomic Evaluation of the Comorbidity-Inflammation Paradigm in Heart Failure With Preserved Ejection Fraction: Results From the PROMIS-HFpEF Study. Circulation. 2020; 142(21):2029-2044. PMC: 7686082. DOI: 10.1161/CIRCULATIONAHA.120.045810. View

18.

Adamo M, Pagnesi M, Ghizzoni G, Estevez-Loureiro R, Raposeiras-Roubin S, Tomasoni D . Evolution of tricuspid regurgitation after transcatheter edge-to-edge mitral valve repair for secondary mitral regurgitation and its impact on mortality. Eur J Heart Fail. 2022; 24(11):2175-2184. PMC: 10086984. DOI: 10.1002/ejhf.2637. View

19.

Zaborska B, Sygitowicz G, Smarz K, Pilichowska-Paszkiet E, Budaj A . Galectin-3 is related to right ventricular dysfunction in heart failure patients with reduced ejection fraction and may affect exercise capacity. Sci Rep. 2020; 10(1):16682. PMC: 7542167. DOI: 10.1038/s41598-020-73634-8. View

20.

Lancellotti P, Pibarot P, Chambers J, La Canna G, Pepi M, Dulgheru R . Multi-modality imaging assessment of native valvular regurgitation: an EACVI and ESC council of valvular heart disease position paper. Eur Heart J Cardiovasc Imaging. 2022; 23(5):e171-e232. DOI: 10.1093/ehjci/jeab253. View